期刊文献+

应用异种脱细胞真皮基质预防腮腺术后味觉出汗综合征 被引量:3

Clinical study of prevention of Frey’s syndrome following parotidectomy using heterogeneous acellular dermal matrix
下载PDF
导出
摘要 目的:评估异种脱细胞真皮基质预防腮腺切除术后味觉出汗综合征的临床疗效。方法:选取腮腺切除术患者142例,抽签分为试验组(70例)和对照组(72例),采用主观症状评价和Minor试验评估2组患者术后味觉出汗综合征的发生情况。采用SPSS18.0软件包对数据进行χ2检验。结果:试验组6/70例(8.57%)、对照组17/72例(23.61%)出现味觉出汗综合征主观症状(χ2=5.91,P<0.05)。Minor试验中,试验组10/70例(14.28%)、对照组37/72例(51.39%)出现Frey综合征客观症状(χ2=22.07,P<0.01),差异显著。结论:腮腺区域切除或浅叶切除术中应用异种脱细胞真皮基质植入,可有效预防味觉出汗综合征。 PURPOSE:To evaluate the clinical effect of heterogeneous acellular dermal matrix on preventing Frey’s syndrome after parotidectomy.METHODS:One hundred and forty-two patients were randomized into two groups,patients in experimental group(70 patients) received heterogeneous acellular dermal matrix graft and while patients in control group(72 patients) didn’t receive heterogeneous acellular dermal matrix graft.The incidence of Frey’s syndrome was evaluated after operation using subjective evaluation Minor’s starch iodine test.The data was analyzed for chi-square test using SPSS18.0 software package.RESULTS:Six of 70(8.57%)in experiment group,17 of 72(23.61%) in control group had subjective symptoms of Frey’s syndrome.There was no significant difference(χ2=5.91,P &lt;0.05) between the two groups.By Minor’s starch iodine test,10(14.28%) cases in experimental group and 37(51.39%) cases in contro1 group had objective symptoms.The difference between the two groups was significant(χ2=22.07,P&lt;0.01).CONCLUSION:The application of heterogeneous acellular dermal matrix could effectively prevent Frey’s syndrome after parotidectomy.
出处 《中国口腔颌面外科杂志》 CAS 2013年第4期345-348,共4页 China Journal of Oral and Maxillofacial Surgery
关键词 异种脱细胞真皮基质 腮腺切除术 味觉出汗综合征 Heterogeneous acellular dermal matrix Parotidectomy Frey’s syndrome
  • 相关文献

参考文献12

  • 1Clayman MA, Clayman SM, Seagle MB. A review of the surgical and medical treatment of Frey syndrome [J]. Ann Plast Surg, 2006, 57(5): 581-584.
  • 2de Bree R, Duyndam JE, Kuilk DJ, et al. Repeated botulinum toxin type A injections to treat patients with Frey syndrome [J]. Arch Otolzryngol Head Neck Surg, 2009, 135(3): 287-290.
  • 3Arad-Cohen A, Blitzer A. Botulinum toxin treatment for symptomatic Frey's syndrome [J]. Otolaryngol Head Neck Surg, 2000, 122(2): 237-240.
  • 4Giannone N, Lo Muzio L, Politi M. Extracapsular lumpectomy and SMAS flap for benign parotid tumours: an early outcome in a small number of cases on Frey's syndrome and facial nerve dysfunction [J]. J Craniomaxillofac Surg, 2008, 36(4): 239-243.
  • 5Yoo YM, Lee JS, Park MC, et al. Dermafat graft after superficial parotidectomy via a modified face-lift incision to prevent Frey syndrome and depressed deformity [J]. J Craniofac Surg, 2011, 22 (3): 1021-1023.
  • 6Torretta S, Pignataro L, Capaccio P, et al. Fat injections for the management of post-parotidectomy Frey syndrome: a technical note [J]. J Craniomaxillofac Surg, 2012, 40(2): 173-176.
  • 7Sinha UK, Saadat D, Doherty CM, et al. Use of AlloDerm implant to prevent frey syndrome after parotidectomy [J]. Arch Facial Plast Surg, 2003, 5(1): 109-112.
  • 8Tugnoli V, Marchese Ragona R, Eleopra R, et al. The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A [J]. Clin Auton Res, 2002, 12 (3): 174- 178.
  • 9Neumann A, Rosenberger D, Vorsprach O, et al. The incidence of Frey syndrome following parotidectomy: results of a survey and follow-up [J]. HNO, 2011, 59(2): 173-178.
  • 10Dulguerov P, Quinodoz D, Cosendai G, et al. Prevention of Frey syndrome during parotidectomy [J]. Arch Otolaryngol Head Neck Surg, 1999, 125(8): 833-839.

同被引文献19

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部